Overview

A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

Status:
Recruiting
Trial end date:
2024-09-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of a single SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)
Phase:
Phase 1
Details
Lead Sponsor:
Brexogen Inc.